NCT03138811View on ClinicalTrials.gov

A Bronchoprovocation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CSJ117 in Adult Subjects With Mild Atopic Asthma

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 18, 2017

Primary Completion Date

July 16, 2019

Study Completion Date

July 16, 2019

Conditions
Asthma
Interventions
DRUG

CSJ117

inhaled once daily dose

DRUG

Placebo Comparator

inhaled once daily dose

Trial Locations (10)

22927

Novartis Investigative Site, Großhansdorf

30625

Novartis Investigative Site, Hanover

55131

Novartis Investigative Site, Mainz

60596

Novartis Investigative Site, Frankfurt

T2N 4N1

Novartis Investigative Site, Calgary

T6G 2B7

Novartis Investigative Site, Edmonton

L8N 3Z5

Novartis Investigative Site, Hamilton

G1V 4G5

Novartis Investigative Site, Québec

S7K 0M7

Novartis Investigative Site, Saskatchewan

Unknown

Novartis Investigative Site, Vancouver

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY